Lantheus Holdings, Inc. business relationships
Companies named in Lantheus Holdings, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Lantheus Holdings, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Lantheus Holdings, Inc.’s annual report 9
“Flyrcado is licensed to GE Healthcare and we are entitled to milestone and royalty-based payments for Flyrcado.” SEC filing
“In May 2025, we paid AstraZeneca a $10.0 million one-time, non-refundable upfront payment to reduce the future royalty obligations owed to AstraZeneca, pursuant to a license agreement between AstraZeneca and Meilleur related to NAV-4694.” SEC filing
“On September 24, 2025, we announced an exclusive licensing agreement for GE Healthcare to develop, manufacture, and commercialize piflufolastat in Japan for prostate cancer diagnostics and companion diagnostic use.” SEC filing
“For example, in addition to our collaboration with Curium on PYLCLARI in Europe, GE Healthcare on Flyrcado in the United States and piflufolastat in Japan and POINT on PNT2003, we have other collaborations to develop and commercialize products.” SEC filing
“Since 2022, we have powered our North Billerica campus with renewable wind energy through a contract with National Grid.” SEC filing
“On August 2, 2023, we sold the right to our RELISTOR royalty asset under our license agreement with Salix Pharmaceuticals, Inc., an affiliate of Bausch Health Companies, Inc.; we retained the rights to future sales-based milestone payments.” SEC filing
“On August 2, 2023, we sold the right to our RELISTOR royalty asset under our license agreement with Salix Pharmaceuticals, Inc., an affiliate of Bausch Health Companies, Inc.; we retained the rights to future sales-based milestone payments.” SEC filing
“...r LNTH-2401 and LNTH-2402 relating to RM2, (B) the development of LNTH-2403 and LNTH-2404, the associated investment in Radiopharm Theranostics Limited ("Radiopharm") and our co-development partnership with Radiopharm relating to the clinical development of our innovative products and product candid...” SEC filing
“Pan-Oncology - In collaboration with Ratio Therapeutics LLC (previously Noria Therapeutics, Inc.), we are developing LNTH-1363S, a novel copper-64 labeled PET imaging agent, targeting fibroblast activation protein alpha.” SEC filing
Companies whose annual reports name Lantheus Holdings, Inc. 5
“We also have a diagnostic partnership with Lantheus for compounds, which bind pathological Tau for use as a PET tracer.” SEC filing
“Under the agreement, we sold to Lantheus Holdings (i) the rights to the” SEC filing
“RAD 203 has been licensed to Lantheus Molecular Imaging ("Lantheus")” SEC filing
“the assignment of the DUNP19 assets to Lantheus Omega, thus terminating the Exclusive License Agreement, dated March 22, 2022, with The” SEC filing
“from a loss of A$65,300 in fiscal 2025 to A$112,396 in fiscal 2026, mainly unwinding of interest in the Lantheus co-collaboration agreement.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.